ANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ANIX
ANIXA BIOSCIENCES INC (ANIX) EV/Sales
As of 16 October 2026, ANIXA BIOSCIENCES INC (ANIX) trades at a EV/Sales of 83.5×. Over the past ten years it has ranged from 0.6× (March 2015) to 211× (April 2023); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 80.1× | (46.26%) |
| FY2021 | 149× | 172.40% |
| FY2019 | 54.7× | 15.09% |
| FY2018 | 47.5× | 64.18% |
| FY2017 | 28.9× | (77.77%) |
| FY2016 | 130× | 5,248.02% |
| FY2015 | 2.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Apr 2023 | 103× | (30.58%) |
| Oct 2021 | 149× | 79.87% |
| Jan 2021 | 82.8× | 42.99% |
| Apr 2019 | 57.9× | 21.90% |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −2.4× |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| ICCC ImmuCell Corporation compare | 3.1× |
| NRXS Neuraxis, Inc. compare | 16.0× |
| RANI Rani Therapeutics Holdings, Inc. compare | 16.3× |
| CBUS Cibus, Inc. compare | 18.9× |
| ATRA Atara Biotherapeutics, Inc. compare | 20.7× |
| ANIX ANIXA BIOSCIENCES INC | 83.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)